Canada places USD 56m monkeypox vaccine order at Bavarian Nordic

Bavarian Nordic’s vaccine is approved for monkeypox in the country, where it is called Imvamune.

Photo: Bavarian Nordic / PR

The Canadian Government has signed a multi-year contract with Bavarian Nordic for supplies of its monkeypox vaccine. The contract has an estimated value of USD 56m.

Bavarian Nordic’s vaccine is approved for both smallpox and monkeypox in the country, where it is marketed under the name Imvamune. Canada is the only country other than the US where it is authorized in both indications.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs